For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 11,111,586 | |||
| General and administrative | 15,028,929 | |||
| Total operating expenses | 26,140,515 | |||
| Loss from operations | -26,140,515 | |||
| Interest expense, net | -195,618 | |||
| Change in fair value of warrants | -60,701 | |||
| Net loss | -26,275,432 | |||
| Basic EPS | -8.08 | |||
| Diluted EPS | -8.08 | |||
| Basic Average Shares | 3,319,812 | |||
| Diluted Average Shares | 3,319,812 | |||
Tevogen Bio Holdings Inc. (TVGN)
Tevogen Bio Holdings Inc. (TVGN)